- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05391893
Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation
October 27, 2023 updated by: Spectrum Health - Lakeland
Emergency Department Atrial Fibrillation Oral Diltiazem Observation Protocol
The primary objective of the study is to reduce hospital admission and decrease time to disposition through establishing an effective treatment protocol for AF and Atrial Flutter in the Emergency Department of Spectrum Health Lakeland.
Secondary outcome is to measure if oral diltiazem is an effective HR controlling agent in AF RVR and Flutter.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
444
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Saint Joseph, Michigan, United States, 49085
- Matthew Hysell
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Heart rate >125
- Systolic BP>110
- Atrial Fibrillation/Flutter confirmed on ECG.
- Meets observation unit requirements (performs certain ADL's (acts of daily living)
- Age>18.
Exclusion Criteria:
- Wolf-Parkinson-White syndrome
- ST Elevation Myocardial Infarction
- Pregnant
- Clinical diagnosis of Sepsis,
- Decompensated HF
- allergy to Diltiazem
- provider discretion
- clinical need for cardioversion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Diltiazem with oral and intravenous treatment
Diltiazem 0.25mg/kg injection, give over 2 minutes, max dose 30mg.
15 minutes following Diltiazem Infusion administer oral Diltiazem 60mg IR Tablet, do not give if BP<100
|
Diltiazem 0.25mg/kg injection, give over 2 minutes, max dose 30mg
Other Names:
|
Placebo Comparator: traditional atrial fibrillation with rapid ventricular response
these patients will receive traditional treatments at provider discretion.
To be included in teh study their initial heart rate must also be over 125, and they must receive at least one intravenous medication for atrial fibrillation with rapid ventricular response.
This will be a heterogenous group of patients receiving digoxin, amiodarone, various beta-blockers, and intravenous diltiazem without oral diltiazem.
|
these patients will receive traditional treatments at provider discretion.
They must receive at least one intravenous medication for atrial fibrillation with rapid ventricular response.
This will be a heterogenous group of patients receiving digoxin, amiodarone, various beta-blockers, and intravenous diltiazem without oral diltiazem.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Admission rate
Time Frame: 1 days
|
This will compare rates of patients admitted between the protocol group and patients treated traditionally
|
1 days
|
Time to heart rate less than 110
Time Frame: 1 days
|
This will compare the total hours from first medicine administration to heart rate less than 110 between the protocol and traditional treatment group
|
1 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of hypotension
Time Frame: 1 day
|
rates of patients experiencing systolic blood pressure less than 90
|
1 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 19, 2020
Primary Completion (Actual)
April 1, 2023
Study Completion (Actual)
April 1, 2023
Study Registration Dates
First Submitted
September 23, 2021
First Submitted That Met QC Criteria
May 21, 2022
First Posted (Actual)
May 26, 2022
Study Record Updates
Last Update Posted (Actual)
October 31, 2023
Last Update Submitted That Met QC Criteria
October 27, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Disease Attributes
- Arrhythmias, Cardiac
- Emergencies
- Atrial Fibrillation
- Atrial Flutter
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Diltiazem
Other Study ID Numbers
- EGME#03-2021
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
Abbott Medical DevicesRecruitingAtrial Fibrillation | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited States, Australia, Belgium, Germany, Spain, Netherlands, France, Austria, Canada, Czechia, Italy, United Kingdom
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
Clinical Trials on Oral
-
Purdue UniversityActive, not recruiting
-
Université de MontréalSt. Justine's HospitalTerminatedObstructive Sleep ApneaCanada
-
EstetraICON Clinical ResearchCompletedVasomotor Symptoms | Menopausal SymptomsUnited States, Canada
-
Pulmagen TherapeuticsCompleted
-
German Institute of Human NutritionLudwig-Maximilians - University of MunichCompletedDiabetes | Pre-diabetesGermany
-
Turning Point Therapeutics, Inc.RecruitingLymphoma | Locally Advanced Solid Tumors | Metastatic Solid Tumors | Primary CNS TumorsUnited States, Korea, Republic of, Spain, Singapore, Taiwan, Australia, Italy, Canada, France, Denmark, United Kingdom
-
Mansoura UniversityCompletedSmall Bowel ObstructionEgypt
-
Applied Molecular TransportActive, not recruitingUlcerative ColitisUnited States, Hungary, Ukraine, Germany, United Kingdom, Belarus, Bulgaria, Canada, France, Georgia, Moldova, Republic of, Poland, Russian Federation, Switzerland
-
Brigham and Women's HospitalCompletedSleep Apnea, ObstructiveUnited States
-
WockhardtCompleted